Pacira BioSciences, Inc. (PCRX) |
|
37.8898 -0.71 (-1.84%)
|
03-24 11:13 |
|
Open: |
38.21 |
Pre. Close: |
38.6 |
|
High:
|
38.48 |
Low:
|
37.79 |
|
Volume:
|
155,301 |
Market Cap:
|
1,741(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 10:46:23 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 49.02  One year: 52.01 |
| Support: |
Support1: 37.83 Support2: 31.47 |
| Resistance: |
Resistance1: 41.97 Resistance2: 44.52 |
| Pivot: |
39.65 |
| Moving Average: |
MA(5): 39.2 MA(20): 40.3
MA(100): 42.48 MA(250): 52.8 |
| MACD: |
MACD(12,26): -0.5 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 8.8 %D(3): 16.1 |
| RSI: |
RSI(14): 40.5 |
| 52-week: |
High: 82.16 Low: 35.34 |
| Average Vol(K): |
3-Month: 547 (K) 10-Days: 452 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PCRX ] has closed above bottom band by 5.2%. Bollinger Bands are 39.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
39.95 - 40.22 |
40.22 - 40.44 |
|
Low:
|
37.97 - 38.23 |
38.23 - 38.44 |
|
Close:
|
38.22 - 38.64 |
38.64 - 38.99 |
|
Company Description |
|
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida. |
Headline News |
Fri, 24 Mar 2023
With Pacira BioSciences, Inc.'s (NASDAQ:PCRX)) price down 6.9% this week, insiders might find some solace having sold US$2.2m worth of shares earlier this year. - Simply Wall St
Wed, 22 Mar 2023
Pacira BioSciences (PCRX) Announces Resignation of Yvonne ... - StreetInsider.com
Sat, 11 Mar 2023
Summit Global Investments Buys 4500 Shares of Pacira ... - MarketBeat
Thu, 09 Mar 2023
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2022 Earnings Call Transcript - Yahoo Finance
Wed, 01 Mar 2023
Pacira's (PCRX) Q4 Earnings Match Estimates, Revenues Fall - Nasdaq
Thu, 23 Feb 2023
LPGA, Pacira BioSciences Partner to Raise Awareness of Non ... - LPGA
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
46 (M) |
| Shares Float |
45 (M) |
|
% Held by Insiders
|
1.1 (%) |
|
% Held by Institutions
|
111.8 (%) |
|
Shares Short
|
4,500 (K) |
|
Shares Short P.Month
|
4,950 (K) |
Stock Financials |
|
EPS
|
3.32 |
|
EPS Est Next Qtl
|
0.1 |
|
EPS Est This Year
|
-0.21 |
|
EPS Est Next Year
|
0.91 |
|
Book Value (p.s.)
|
14.85 |
|
Profit Margin (%)
|
3.1 |
|
Operating Margin (%)
|
15.9 |
|
Return on Assets (ttm)
|
4.2 |
|
Return on Equity (ttm)
|
2.7 |
|
Qtrly Rev. Growth
|
31.1 |
|
Gross Profit (p.s.)
|
7.53 |
|
Sales Per Share
|
14.25 |
|
EBITDA (p.s.)
|
3.89 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
126 (M) |
|
Levered Free Cash Flow
|
88 (M) |
Stock Valuations |
|
PE Ratio
|
11.45 |
|
PEG Ratio
|
0.5 |
|
Price to Book value
|
2.56 |
|
Price to Sales
|
2.67 |
|
Price to Cash Flow
|
13.83 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
